0001209191-19-044887.txt : 20190806 0001209191-19-044887.hdr.sgml : 20190806 20190806184559 ACCESSION NUMBER: 0001209191-19-044887 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190802 FILED AS OF DATE: 20190806 DATE AS OF CHANGE: 20190806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRIEDMAN PAUL A CENTRAL INDEX KEY: 0001236927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 191003462 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION STREET 2: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-02 0 0000879169 INCYTE CORP INCY 0001236927 FRIEDMAN PAUL A 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 1 0 0 0 Common Stock 2019-08-02 4 M 0 22066 18.32 A 277597 D Common Stock 15000 I By Grat Common Stock 2019-08-02 4 S 0 22066 84.41 D 255531 D Common Stock 15000 I By Grat Common Stock 2019-08-06 4 M 0 77934 18.32 A 333465 D Common Stock 15000 I By Grat Common Stock 2019-08-06 4 S 0 77934 82.20 D 255531 D Common Stock 15000 I By Grat Non-Qualified Stock Option (right to buy) 18.32 2019-08-02 4 M 0 22066 0.00 D 2020-02-08 Common Stock 22066 77934 D Non-Qualified Stock Option (right to buy) 18.32 2019-08-06 4 M 0 77934 0.00 D 2020-02-08 Common Stock 77934 0 D Represents weighted average sale price. Actual sale prices ranged from $84 - $84.92. Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019. Represents weighted average sale price. Actual sale prices ranged from $82.00 - $82.68. Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. /s/ Michael Purvis, Attorney-In-Fact 2019-08-06 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

Power of Attorney

	Know all by these presents that the undersigned hereby constitutes and appoints
each of Maria E. Pasquale, Christiana Stamoulis, Michael J. Purvis and Paul
Trower, signing singly, the undersigned's true and lawful attorney-in-fact to:

(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of Incyte Corporation (the "Company"), Forms 3, 4,
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;

(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the United States Securities and Exchange Commission and any stock
exchange or similar authority; and

(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of May 7, 2019.



							/s/ Paul A. Friedman
							Paul A. Friedman